HVTN 702 vaccine - Emavundleni Research Centre
CAPE TOWN, SOUTH AFRICA - Wednesday 30 November 2016, Dr Carl W Dieffenbach, Director of the Division of AIDS in the United States National Institute for Allergy and Infectious Diseases during the launch of a major study to test the efficacy of a vaccine to prevent HIV infection at the Emavundleni Research Centre in Old Crossroads, Cape Town. With more than 1 000 people in South Africa becoming infected with HIV each day, a successful HIV vaccine is seen as the key to ending the epidemic. This new preventive vaccine efficacy trial, called HVTN 702, is a critically important study and its start is a special moment in HIV research. HVTN 702 is the only current HIV vaccine efficacy trial in the world and is being conducted solely in South Africa. It has been seven years since the world last saw the start of an efficacy trial of an HIV vaccine. The South African study will test a modified form of the vaccine regimen used in RV144, a trial conducted in Thailand, which reported in 2009 that the candidate vaccine was 31.2% effective in preventing new HIV infections 3.5 years after first vaccination. HVTN 702 builds on the foundation of the promising Thai trial findings and seeks to increase the level of efficacy and durability of the vaccine response. If HVTN 702 is shown to be effective against new infections, this South African trial could lead to the licensing of the world’s first HIV vaccine.
Photo by Roger Sedres/ImageSA